- Home
- BIDU vs CANF Comparison
BIDU vs CANF Comparison
Compare BIDU & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIDU | CANF |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.9B | 4.8M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | BIDU | CANF |
|---|---|---|
| Price | $123.52 | $0.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $144.23 | $3.25 |
| AVG Volume (30 Days) | ★ 2.3M | 1.2M |
| Earning Date | 11-18-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.25 | N/A |
| Revenue | ★ $18,325,514,127.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | $4.78 | N/A |
| P/E Ratio | $37.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $74.71 | $0.17 |
| 52 Week High | $149.51 | $2.33 |
Technical Indicators
Market Signals| Indicator | BIDU | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 22.66 |
| Support Level | $121.80 | $0.26 |
| Resistance Level | $125.37 | $0.30 |
| Average True Range (ATR) | 2.91 | 0.02 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 40.16 | 3.41 |
Price Performance
Historical ComparisonAbout BIDU Baidu Inc. ADS
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 70% of core revenue from online marketing services from its search engine in 2024. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).